<DOC>
	<DOCNO>NCT02737059</DOCNO>
	<brief_summary>This single center , randomize , double-blind , placebo-controlled , parallel-group , Phase I study effect naloxegol , novel mu-opioid antagonist , gastrointestinal colonic transit presence absence mu-opiate , codeine . There need develop effective medication treatment opiate-induced constipation motility disorder . Currently available opiate complicate addictive potential induction troublesome constipation .</brief_summary>
	<brief_title>Effect Naloxegol Gastric , Small Bowel , Colonic Transit Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Codeine</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Inclusion criterion : Body Mass Index ( BMI ) 19 30 kg/m^2 absolute weight 45 100 kg . male female . Females nonpregnant , nonlactating , postmenopausal least one year ( evidence last menses 12 month Day 0 ) , surgically sterile , willing use clinicallyapproved method contraception 35 day prior Day 0 30 day last dose study medication Males surgically sterile willing use clinically approve method contraception Day 0 30 day last dose study medication . Absence gastrointestinal symptom unless deem clinically significant Investigator . Able understand willing sign inform consent Negative urine drug screen screen Exclusion criterion : Structural metabolic diseases/conditions affect gastrointestinal system , functional gastrointestinal disorder . For screening , three `` YES '' responses Bowel Disease Questionnaire use exclude subject irritable bowel syndrome . Use drug agent within past 2 week plan use subsequent 4 week study period : Alter GI transit include laxative , magnesium aluminumcontaining antacid , prokinetic , erythromycin , narcotic , anticholinergic , tricyclic antidepressant , Selective serotonin reuptake inhibitor ( SSRI ) new antidepressant . Analgesic drug include opiate , NSAID , cyclooxygenase2 ( COX 2 ) inhibitor Use nonprescription prescription medication within 7 day within five halflives prior Day 0 particular medication . Note : Low stable dos thyroid replacement , estrogen replacement , birth control pills depot injection , use acetaminophen need basis permissible . A score great equal 11 either score obtain Hospital Anxiety Depression Scale Positive urine drug screen screen Female subject pregnant breast feeding . Clinical evidence ( include physical exam , previous laboratory test ) significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematological , neurological , psychiatric , disease interfere objective study . Patients previously high transaminase level ( AST , ALT ) may retested result less 1.5 time upper limit normal include long underlie know liver disease . Symptoms significant clinical illness precede two week . Participation another clinical study within past 30 day . Subjects know allergy hypersensitive multiple drug compound ( great equal 3 drug compound ) , naloxegol opioid antagonist , codeine sulfate , eggs component study medication Daily use tobacco product within 6 month prior Day 0 Previous exposure naloxegol Any condition prior therapy , opinion Investigator , would make subject unsuitable study Contraindications use naloxegol accordance FDA guidance : suspect GI obstruction increase risk recurrent obstruction ; concomitant use strong CYP3A4 inhibitor clarithromycin ketoconazole Concomitant treatment moderate CYP3A4 inhibitor ( diltiazem , erythromycin , verapamil ) strong CYP3A4 inducer ( rifampin ) opioid antagonist . History substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>